French scientist Etienne-Emile Baulieu, inventor of the abortion pill, dies at 98
ROME — French scientist Etienne-Emile Baulieu, best known as the inventor of the abortion pill, died on Friday aged 98 at his home in Paris, his institute said in a statement.
Article content
Both a doctor and a researcher, Baulieu was known around the world for the scientific, medical and social significance of his work on steroid hormones.
Article content
'His research was guided by his attachment to the progress made possible by science, his commitment to women's freedom, and his desire to enable everyone to live better, longer lives,' the Institut Baulieu said in the statement posted on its website.
Article content
Born Etienne Blum in Strasbourg on Dec. 12, 1926, he took the name 'Emile Baulieu' when he joined the French Resistance against the Nazi occupation at the age of 15.
Article content
Article content
An endocrinologist with a doctorate in medicine completed in 1955 and one in science eight years later, in 1963 Baulieu founded a pioneering research unit working on hormones at INSERM, the French institute for health and medical research. He remained as head of the unit until 1997.
Article content
He is best known for his development, in 1982, of RU 486, the so-called 'abortion pill' that changed the lives of millions of women throughout the world, offering them the possibility of voluntary medical termination of pregnancy, in physical and psychological safety.
Article content
The Institut Baulieu said it was 'a non-invasive method, less aggressive and less delayed than surgery,' noting that following his discovery the researcher faced fierce criticism and even threats from opponents of women's abortion rights.
Article content
Article content
'Even today, access to this method is opposed, banned in some countries, and is currently being challenged in the United States, where it is the most widely used abortion method,' the institute added.
Article content
Article content
Baulieu's research into DHEA, a hormone whose secretion and anti-aging activity he had discovered, led him to work on neurosteroids — or steroids of the nervous system. He also developed an original treatment to combat depression, for which a clinical trial is currently underway in several university hospitals.
Article content
In 2008, he founded the Institut Baulieu to understand, prevent and treat neurodegenerative diseases such as Alzheimer's.
Article content
Honored with the grand crosses of the Legion d'honneur (legion of honor) and the Ordre national du Merite (national order of merit), he was elected to the French Academy of Sciences in 1982, which he chaired in 2003 and 2004.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
3 hours ago
- CBC
Canadian WW I soldier identified 108 years after his death
It's been a mystery for more than 100 years, but the Canadian military has identified a soldier killed in the First World War as Capt. William Webster Wilson. Wilson, an accomplished soldier, left Lindsay, Ont., to fight in France before he was declared missing on Oct. 9, 1916 following a fierce fight known as the Battle of the Ancre Heights – part of the larger Somme offensive. The defence department said his grave was identified by Canada's Casualty Identification Review Board through the use of historical and archival research. "Captain Wilson gave his life to protect our great country and his identification is a reminder of the sacrifices that he and all Canadians who served have made—as well as their families," said Defence Minister David McGuinty in a news release. Wilson's family has been notified about the news and a headstone rededication ceremony will soon take place at Adanac Military Cemetery, in Miraumont, France. Born in Edinburgh, Scotland, Wilson immigrated to Canada and worked in Toronto at the Bank of Montreal, later joining the branch in Lindsay. There, he became a captain with the 45th Victoria Regiment before the declaration of the First World War. He enlisted on Sep. 23, 1914, after travelling to Valcartier, Que. with thousands of men after the war broke out, according to the defence department. "Time will never erase the debt we owe to Canadians like Captain Wilson, who more than 100 years ago sacrificed everything to protect the freedoms we enjoy today," said Veteran Affairs Minister Jill McKnight in a news release. The Commonwealth War Graves Commission first received a report from external researchers regarding a grave of an unidentified captain of the 16th Canadian Battalion back in 2016. The grave's identity was later determined to be Wilson's and confirmed by a review board consisting of historians and forensic scientists. The Casualty Identification Program was established in 2007 and started to formally confirm unidentified graves six years ago. When their identity is successfully found, the headstone is replaced featuring their full identity with a small rededication ceremony.
National Post
5 hours ago
- National Post
J.K. Rowling, Piers Morgan slam ‘woke brigade,' call for cancellation of controversial boxer
J.K. Rowling is leading the charge, calling for Olympic boxer Imane Khelif to be stripped of a gold medal after a leaked report revealed the controversial champion has 'male' chromosomes. Article content The medical test on Khelif from the 2023 World Championships comes less than two days after World Boxing ruled the boxer would need to undergo sex screening to be eligible for any future appearances in female events. Article content Article content Article content Last year, the 26-year-old represented Algeria and won gold at the Paris Olympic Games. Article content Rowling, who has long criticized biological males competing in women's sports, took to X to call the news 'a win for women because they won't be battered to death in the ring by men.' Article content She responded to a post by someone who suggested the testing was a violation against Khelif. Article content 'If you had any idea what physical tests women go through routinely in their lives you'd know a cheek swab is no bigger deal than flossing your teeth,' the Harry Potter creator wrote. 'Any more moronic questions, wing them over.' Article content It's a win for women because they won't be battered to death in the ring by men. If you had any idea what physical tests women go through routinely in their lives you'd know a cheek swab is no bigger deal than flossing your teeth. Any more moronic questions, wing them over. — J.K. Rowling (@jk_rowling) June 2, 2025 Article content Article content Former collegiate swimmer Riley Gaines, who competed against trans athlete Lia Thomas, agreed. Article content 'A cheek swab is far from invasive — certainly less invasive than having your brain prodded through your nose like they did with COVID tests, and definitely less invasive than being punched in the face by a man.' she wrote on X. Article content The women's sports advocate added in another post: 'To all the people that insisted Imane Khelif was a woman because his passport said so, you were wrong. We were right. Sincerely, People with functioning eyes and a shred of honesty.' Article content To all the people that insisted Imane Khelif was a woman because his passport said so, You were wrong. We were right. Sincerely, People with functioning eyes and a shred of honesty — Riley Gaines (@Riley_Gaines_) June 1, 2025
Globe and Mail
5 hours ago
- Globe and Mail
Bristol Myers Collaborates With BNTX for Oncology Candidate
BMY announced a strategic collaboration agreement with BioNTech BNTX. Both companies have entered into an agreement for the global co-development and co-commercialization of BioNTech's investigational bispecific antibody BNT327 across numerous solid tumor types. BNT327 is a novel investigational bispecific antibody combining two complementary, validated mechanisms in oncology into a single molecule. Shares of BNTX surged on the deal announcement. Shares of Bristol Myers lost 12.8% year to date compared with the industry 's decline of 2.2%. More on BMY & BNTX Agreement Per the terms, BMY and BNTX will jointly develop and commercialize BNT327, including the development of BNT327 as monotherapy and in combination with other products. Both BMY and BNTX own the right to develop BNT327 independently in further indications and combinations, including combinations of BNT327 with proprietary pipeline assets. Per the terms, BMY will make an upfront payment of $1.5 billion to BioNTech. In addition, BNTX will also receive $2 billion in non-contingent anniversary payments through 2028. BioNTech is also eligible to receive up to $7.6 billion in additional development, regulatory and commercial milestones. Both the companies will jointly share development and manufacturing costs along with profits on an equal basis. BNT327, a next-generation bispecific antibody candidate, targets PD-L1 and VEGF-A. It is currently being evaluated in multiple ongoing trials with more than 1,000 patients treated to date, including phase III studies with registrational potential evaluating BNT327 as first-line treatment in extensive stage small cell lung cancer (ES-SCLC) and non-small cell lung cancer (NSCLC). A phase III study evaluating the candidate in triple negative breast cancer (TNBC) is planned to start by the end of 2025. Data from ongoing trials (on a preliminary basis) underscore the potential for combining anti-PD-L1 and anti-VEGF-A – two well-established therapeutic targets – into a single molecule to deliver synergistic clinical benefits for patients across multiple tumor types. BMY Looks to Diversify Business BMY is depending on newer drugs like Opdualag, Reblozyl and Breyanzi to stabilize its revenue base as its legacy drugs face generic competition. BMY earlier won FDA approval for xanomeline and trospium chloride (formerly KarXT), an oral medication for the treatment of schizophrenia, in adults, under the brand name Cobenfy. The approval broadens BMY's portfolio. Cobenfy represents the first new pharmacological approach to treating schizophrenia in decades. This drug is expected to contribute meaningfully to BMY's top line in the coming years. BMY has experienced a few pipeline setbacks in recent months, which negatively impacted its share price. The late-stage ODYSSEY-HCM study evaluating cardiovascular drug Camzyos for the treatment of adult patients with symptomatic New York Heart Association (NYHA) class II-III non-obstructive hypertrophic cardiomyopathy did not meet its dual primary endpoints. The top-line results from the phase III ARISE study on schizophrenia drug Cobenfy were also disappointing. The study is evaluating the efficacy and safety of the drug as an adjunctive treatment to atypical antipsychotics in adults with inadequately controlled symptoms of schizophrenia. Developing bispecific antibodies that target two proteins, namely PD-1 and VEGF, has lately been one of the lucrative areas in cancer treatment. In November, Merck signed a deal with China-based LaNova Medicines for the latter's PD-1xVEGF targeting bispecific antibody candidate, LM-299. The latest entrant into this space is Pfizer PFE, which recently entered a multi-billion-dollar deal with Chinese biotech 3SBio for the latter's PD-1/VEGF bispecific antibody SSGJ-707. The deal is expected to be complete in third-quarter 2025. BMY's Zacks Rank & Stocks to Consider Bristol Myers currently carries a Zacks Rank #3 (Hold). A couple of better-ranked stocks in the pharma/biotech sector are Novartis NVS and Pfizer, both carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. The Zacks Consensus Estimate for Novartis' 2025 earnings per share (EPS) has risen from $8.47 to $8.74 over the past 60 days. EPS estimates for 2026 have jumped 20 cents to $9.02 during this timeframe. The stock has risen 18.6% so far this year. Pfizer's 2025 EPS estimate has risen from $2.97 to $3.06 in the past 60 days, while that for 2026 has gone up from $2.99 to $3.09 over the same timeframe. Zacks' Research Chief Names "Stock Most Likely to Double" Our team of experts has just released the 5 stocks with the greatest probability of gaining +100% or more in the coming months. Of those 5, Director of Research Sheraz Mian highlights the one stock set to climb highest. This top pick is among the most innovative financial firms. With a fast-growing customer base (already 50+ million) and a diverse set of cutting edge solutions, this stock is poised for big gains. Of course, all our elite picks aren't winners but this one could far surpass earlier Zacks' Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months. Free: See Our Top Stock And 4 Runners Up Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Novartis AG (NVS): Free Stock Analysis Report Bristol Myers Squibb Company (BMY): Free Stock Analysis Report Pfizer Inc. (PFE): Free Stock Analysis Report BioNTech SE Sponsored ADR (BNTX): Free Stock Analysis Report
